Belite Bio files tinlarebant MAAs in UK, Singapore and Switzerland
Belite Bio has submitted Marketing Authorization Applications (MAAs) for tinlarebant to regulators in the United Kingdom, Singapore, and Switzerland, using the Access Consortium framework to pursue simultaneous review across all three jurisdictions. If approved, the oral therapy would become the first sanctioned treatment for Stargardt disease type 1 (STGD1) in each of those markets.
STGD1 is a rare, inherited retinal disease driven by mutations in the ABCA4 gene. The progressive accumulation of bisretinoid toxins in the retina leads to irreversible vision loss, typically presenting in childhood or adolescence. No approved pharmacological option currently exists in any of the three markets covered by the Access Consortium submission, nor in the United States or Japan, where separate applications are also under review.
Regulatory landscape
The Access Consortium groups the health authorities of Australia, Canada, Singapore, Switzerland, and the United Kingdom into a collaborative review framework intended to reduce duplication of effort and shorten overall review timelines for applicants. Belite Bio's three-market submission is coordinated across the Health Sciences Authority (HSA), the Medicines and Healthcare products Regulatory Agency (MHRA), and Swissmedic, allowing the agencies to share assessment work in parallel.
In the United States, Belite Bio's New Drug Application has been accepted with Priority Review, carrying a Prescription Drug User Fee Act target action date of 12 February 2027. A separate submission in Japan is proceeding under the SAKIGAKE Designation System, which provides accelerated review for innovative therapies addressing serious unmet medical need. Tinlarebant has also secured Breakthrough Therapy, Fast Track, and Rare Pediatric Disease designations in the US, as well as Orphan Drug status in the US, Europe, Japan, and Switzerland.
Tom Lin, Chairman and Chief Executive Officer of Belite Bio, said the company was "confident in our robust data showing tinlarebant's ability to slow the growth rate of retinal lesions compared to placebo" and described the submissions as an important step toward making the drug globally available.
Mechanism and clinical evidence
Tinlarebant works by modulating serum retinol binding protein 4 (RBP4), the sole carrier protein responsible for transporting retinol from the liver to the eye. By reducing retinol supply to the retina, it limits the formation of bisretinoids, the by-products of the visual cycle implicated in STGD1 progression. The same mechanism is also being explored in geographic atrophy, the advanced form of dry age-related macular degeneration.
Belite Bio completed a Phase 3 trial, DRAGON, in adolescent and adult STGD1 patients, which the company says met its primary endpoint. An ongoing Phase 2/3 study, DRAGON II, continues to enrol in the same indication, while the Phase 3 PHOENIX trial is evaluating tinlarebant in geographic atrophy.
The STGD1 space remains largely without approved therapies, a situation that has attracted a number of clinical-stage programmes from other developers targeting the visual cycle or gene-correction approaches. Should tinlarebant reach approval in the US on the February 2027 PDUFA date and subsequently in Access Consortium markets, Belite Bio would be positioned as the first mover in a rare-disease segment where pricing leverage and orphan protections could support a commercially viable launch at relatively modest patient volumes. Investors will be watching regulatory agency feedback and any updated clinical data from DRAGON II as the primary near-term read-outs.